MMED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MiniMed Group Inc (MMED) is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. My view is positive because the stock has strong analyst support, several recent Buy ratings with price targets mostly around $20-$27, and a favorable long-term product/catalyst pipeline. At the current pre-market price of 11.51, the stock still sits well below most analyst targets, making the setup attractive for a patient long-term buyer who wants to enter now rather than wait for a perfect pullback.
The short-term technical picture is mixed but improving. MACD histogram is positive and expanding, which supports near-term momentum. RSI_6 at 53.04 is neutral, so the stock is not overbought. However, the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, which means the broader trend is still below a full bullish confirmation. Price is currently above the pivot at 11.359 and below R1 at 11.947, so the stock is trading near a short-term decision area. Overall, technicals say the stock is not in a strong downtrend anymore, but long-term trend confirmation is still developing.
Recent news is supportive. MiniMed will present at the American Diabetes Association Scientific Sessions from June 5-8, showcasing MiniMed Go and MiniMed Flex systems, connected solutions, smartGuard automation, and updated sensor portfolio data. This is a clear event-driven catalyst that can reinforce investor interest and highlight product execution. Analyst sentiment is also broadly positive, with multiple firms initiating or reiterating Buy/Overweight views and target prices near or above $20, while Goldman previously saw even higher upside potential.
The main negatives are the still-bearish longer-term moving average structure and mixed options positioning. Piper Sandler is the lone notable cautious voice, rating the stock Neutral with a $16 target and arguing MiniMed may lag competitors in form factor and ease of use. In addition, hedge fund and insider trading trends are neutral, so there is no strong insider or institutional buying signal to reinforce conviction. No recent politician or influential figure trading was reported, and no congress trading data is available.
Latest quarter financials are not available in the provided data, so a quarter-by-quarter financial review cannot be completed. The only financial clue in the dataset is analyst commentary stating that the quarter ending January showed strong international growth and that the company is working through post-separation complexity from Medtronic. That suggests operating momentum, but there is no reported revenue, earnings, or margin data here to verify the latest season's performance directly.
Analyst sentiment is bullish overall and has improved further recently. BofA lowered its target to $20 from $27 but kept a Buy rating, while Benchmark initiated coverage with a Buy and $20 target, Deutsche Bank initiated Buy at $20, Barclays started Overweight at $26, William Blair started Outperform, and Goldman Sachs initiated Buy with a $67 target. The only notable cautious view is Piper Sandler's Neutral at $16. Wall Street’s pros see a compelling valuation, broad diabetes product strategy, international growth, and pipeline upside; the cons view focuses on competitive execution risk, product usability concerns, and medtech valuation reset pressure. Overall, the pro side clearly outweighs the con side.
